Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Cerevel Therapeutics Holdings, Inc. (CERE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
08/02/2023 8-K Quarterly results
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer"
05/03/2023 8-K Quarterly results
02/22/2023 8-K Quarterly results
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
12/19/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., November 8, 2022 –"
08/16/2022 8-K Quarterly results
08/12/2022 8-K Quarterly results
08/01/2022 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass"
06/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents and marketable securities as of March 31, 2022; additional $37.5M from tavapadon risk-sharing arrangement received in April 2022 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass"
03/01/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 Submissions of additional PK/PD data for CVL-231 in schizophrenia accepted for presentation at the Annual Meeting of the American College of Neuropsychopharmacology Conference call and webcast scheduled today at 8:00 a.m. ET CAMBRIDGE, Mass"
09/21/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
Docs: "Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia Raised $328 million in net proceeds from follow-on offering of common stock and announced redemption of outstanding public warrants Received Fast Track designation and initiated screening in Phase 2a trial of CVL-871 in dementia-related apathy Virtual R&D Update Event scheduled for October 7, 2021 Conference call and webcast scheduled today at 8:00 a.m. EDT CAMBRIDGE, Mass., August 11, 2021 --"
07/30/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : July 30, 2021 CEREVEL THERAPEUTICS HOLDINGS, INC. Delaware 001-39311 85-3911080 222 Jacobs Street, Suite 200 Cambridge, MA 02141 304-2048 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to ...",
"Cerevel Therapeutics Announces Redemption of Public Warrants CAMBRIDGE, Mass., July 30, 2021 - Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that on August 30, 2021 at 5:00 p.m. ET, it will redeem all of its outstanding public warrants to purchase shares of the Company's common stock that were issued under the Warrant Agreement, dated as of June 9, 2020, by and between the Company and Continental Stock Transfer & Trust Company , as warrant agent. Each such public warrant may be exercised by the holder thereof to purchase one share of the Company's common stock at the exercise price of $11.50 per public warrant. Any such public warrants that remain unexercised following 5:00 p.m. ET on August 30, 2021 will...",
"Notice of Redemption"
07/02/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 1, 2021 CEREVEL THERAPEUTICS HOLDINGS, INC. Delaware 001-39311 85-3911080 222 Jacobs Street, Suite 200 Cambridge, MA 02141 304-2048 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to R...",
"Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock"
06/29/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 29, 2021 CEREVEL THERAPEUTICS HOLDINGS, INC. Delaware 001-39311 85-3911080 222 Jacobs Street, Suite 200 Cambridge, MA 02141 304-2048 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to ...",
"Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia",
"Corporate presentation of Cerevel Therapeutics Holdings, Inc."
06/16/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
04/21/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
Docs: "Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results"
01/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Waiver, by and among Cerevel Therapeutics Holdings, Inc. and the investors party thereto",
"Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors Cambridge, Mass. - January 21, 2021 - Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed the Honorable Deval Patrick and Deborah Baron to serve as independent members of its Board of Directors. Mr. Patrick, a former two-term governor of Massachusetts, is an experienced business and government leader with a deep understanding of the life sciences ecosystem. He currently serves as a director at Global Blood Therapeutics, Amwell, Twilio, and Environmental Impact Acquisition Corp. He is also the founder and chairperson of the TogetherFund, a political action committee that supports prog..."
12/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Non-Employee Director Compensation Policy",
"Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors"
11/20/2020 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from Withum to the Securities and Exchange Commission",
"Letter from Withum to the Securities and Exchange Commission"
11/16/2020 8-K Quarterly results
Docs: "Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights"
11/02/2020 8-K Director compensation was amended/approved
Docs: "Amended and Restated Registration and Shareholder Rights Agreement, by and among Cerevel Therapeutics Holdings, Inc. and the stockholders party thereto",
"Lease Agreement, by and between Cerevel Therapeutics, LLC and FHF I 131 Dartmouth, LLC",
"Lease Agreement, by and between Cerevel Therapeutics, LLC and DW Propco JK, LLC, as amended on September 1, 2020",
"Forms of Award Agreements under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan",
"Form of Subscription Agreement (incorporated by reference to Annex F to the Proxy Statement/Prospectus)",
"Form of Subscription Agreement (incorporated by reference to Annex F to the Proxy Statement/Prospectus)",
"Employment Agreement, by and between Cerevel Therapeutics, LLC and John Renger",
"Senior Executive Cash Incentive Bonus Plan",
"Severance Benefits Policy for Specified C-Suite Executives",
"Non-Employee Director Compensation Policy"
10/26/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 26, 2020 ARYA SCIENCES ACQUISITION CORP II Cayman Islands 001-39311 98-1533670 51 Astor Place, 10th Floor 10003 284-2300 Registrant's telephone number, including area code Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-..."
10/21/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 21, 2020 ARYA SCIENCES ACQUISITION CORP II Cayman Islands 001-39311 98-1533670 51 Astor Place, 10th Floor 10003 284-2300 Registrant's telephone number, including area code Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"ARYA Sciences Acquisition Corp II Announces Extraordinary General Meeting Teleconference Details"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy